HK:2592 Stock Latest News
Company AnnouncementsCloudbreak Pharma Forms Special Committee as Interim Report Delayed and Trading Remains Suspended1M ago2592
Company AnnouncementsCloudbreak Pharma Adds Two Independent Non-Executive Directors Amid Trading Suspension1M ago2592- Company AnnouncementsCloudbreak Pharma Restructures Board Roles and Committee Memberships1M ago2592
Company AnnouncementsCloudbreak Pharma Shares Suspended in Hong Kong Amid IPO Manipulation Probe1M ago2592
Company AnnouncementsCloudbreak Pharma Advances Ophthalmic Pipeline as Trading Suspension Persists1M ago2592
Company AnnouncementsCloudbreak Pharma Swings to Loss as R&D Spend Rises in First Half 20262M ago2592Company AnnouncementsCloudbreak Pharma Sets Board Meeting to Review Interim Results and Dividend2M ago2592
Company AnnouncementsCloudbreak Pharma Wins FDA Safety Clearance to Begin CBT-358 Clinical Investigation3M ago2592
Company AnnouncementsCloudbreak Pharma strengthens governance with new company secretary3M ago2592
Company AnnouncementsCloudbreak Pharma Wins Near-Unanimous Shareholder Support at 2026 AGM4M ago2592
Company AnnouncementsCloudbreak Pharma sets up US$15 million flexible share subscription facility4M ago2592
Company AnnouncementsCloudbreak Reaches Key Phase 3 Milestone for First-in-Class Pterygium Drug CBT-0015M ago2592
Company AnnouncementsCloudbreak Pharma Redirects IPO Proceeds to Broaden R&D Pipeline5M ago2592Company AnnouncementsCloudbreak Pharma Sets 2026 AGM to Approve Accounts and Renew Share Issuance Mandate5M ago2592
Company AnnouncementsCloudbreak Pharma delays annual meeting to late June5M ago2592- Company AnnouncementsCloudbreak Pharma Wins FDA Safety Nod to Advance Presbyopia Drug CBT-1996M ago2592
Company AnnouncementsCloudbreak Pharma Fully Redeems Fund, Clarifies Independence After Use-of-Proceeds Deviation6M ago2592
Company AnnouncementsCloudbreak Pharma to Redeem HK$47.1 Million Fund Investment After Use‑of‑Proceeds Deviation7M ago2592
Company AnnouncementsCloudbreak Pharma Narrows Annual Loss Despite Higher R&D Spending7M ago2592Company AnnouncementsCloudbreak Pharma Withdraws China IND for CBT-009, Refocuses Ophthalmic Pipeline Strategy7M ago2592
Company AnnouncementsCloudbreak Pharma Sets March 30 Board Meeting to Approve 2025 Annual Results7M ago2592